Clinical trial NCT02287285: Determinants of Diabetes Remission After Gastric Bypass Surgery
Official title: Long Term Change of GLP-1 Insulinotropic Effect After GBP Surgery
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: EARLY_PHASE1
Conditions: Type 2 Diabetes Mellitus
Keywords: Type 2 Diabetes Mellitus
Gastric Bypass Surgery
Exendin9
Lead sponsor: Columbia University
Sponsor class: OTHER
Collaborators: name: National Institutes of Health (NIH)
name: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
First posted: 2014-11-10
Enrollment: 25
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Longitudinal study of beta cell function up to 2 years after GBP surgery. Evaluation of the role of endogenous glucagon-like peptide-1 (GLP-1).

Detailed description: The increased prevalence of obesity and type 2 diabetes (T2DM) has resulted in a surge in the number of patients seeking surgical weight loss. Gastric bypass surgery (GBP) results in 30-40% body weight loss with resolution of T2DM in 40-80% of cases. The mechanisms by which T2DM improves after GBP are unclear. Glycemic control occurs long before significant weight loss, suggesting that the nature of the procedure, rather than the weight loss, is responsible for the T2DM improvement. Recent data have singled out the role of the gut hormones known as incretins in diabetes improvement after GBP. The current proposal will study 1) whether the short and long term change in the gut hormone incretins after GBP results in improved insulin secretion in response to the administration of oral and IV glucose, in patients with diabetes undergoing GBP surgery; 2) the factors responsible for diabetes remission - or lack of - after GBP. The investigators wish to apply our finding to define better surgical outcome on diabetes.

Eligibility criteria: Inclusion Criteria:

* Patients with a wide range of T2DM (duration, treatment modalities and control, in or not in remission) and scheduled for GBP surgery
* Blood pressure is under at least moderate control \<160/100 mmHg
* Patients can be on dyslipidemia medications but need fasting triglyceride \< 600 mg/dl
* Patients without recent (last 6 months) history of cardiovascular disease (CVD)
* BMI \> 35 and \< 55 kg/m2 prior to GBP surgery

Exclusion Criteria:

* Active cancer
* Unstable angina
* Recent stroke
* Current therapy that may affect glucose metabolism such as glucocorticoids, HIV medications, etc
* Active infection
* Kidney failure
* Severe liver dysfunction
* Severe respiratory or cardiac failure
* History of allergic reaction to exendin 9-39
* History of pancreatitis, history of cholelithiasis, history of alcoholism
* Presence of high triglyceride levels (\>600 ng/dl)
* Pregnancy (a pregnancy test will be done prior to enrollment and prior to each procedure in all premenopausal women)

Primary outcomes:
measure: Beta Cell Sensitivity (BCS)
timeFrame: at 2 years post GBP surgery
Secondary outcomes:
measure: Insulin Secretion Rate (ISR) after OGTT
timeFrame: 2 years post GBP surgery
measure: Insulin Secretion Rate (ISR) after GGI
timeFrame: 2 years post GBP surgery
measure: Maximal Beta Cell Function
timeFrame: 2 years post GBP surgery
Other outcomes:
Locations:
city: New York
country: United States
facility: New York Obesity Research Center, Columbia University
state: New York
Study officials:
affiliation: New York Obesity Nutrition Research Center, Columbia University
name: Blandine Laferrere, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Prasad M, Mark V, Ligon C, Dutia R, Nair N, Shah A, Laferrere B. Role of the Gut in the Temporal Changes of beta-Cell Function After Gastric Bypass in Individuals With and Without Diabetes Remission. Diabetes Care. 2022 Feb 1;45(2):469-476. doi: 10.2337/dc21-1270.
citation: Shah A, Holter MM, Rimawi F, Mark V, Dutia R, McGinty J, Levin B, Laferrere B. Insulin Clearance After Oral and Intravenous Glucose Following Gastric Bypass and Gastric Banding Weight Loss. Diabetes Care. 2019 Feb;42(2):311-317. doi: 10.2337/dc18-1036. Epub 2018 Dec 6.